Company Overview of Neuro3d S.A.
As of March 29, 2007, Neuro3d S.A. was acquired by Evotec AG. Neuro3d S.A., a biopharmaceutical company, engages in the discovery and development of treatment drugs for psychiatric disorders. Its drug portfolio includes ocaperidone for schizophrenia patients and ND1251 for the treatment of depression, as well as ND7001, a psychoactive drug with antidepressant-like and anxiolytic effects in animals. Neuro3d S.A. was founded in 2000 and is headquartered in Mulhouse, France.
130, rue de la Mer Rouge
Founded in 2000
33 3 89 36 91 70
33 3 89 36 91 78
Key Executives for Neuro3d S.A.
Neuro3d S.A. does not have any Key Executives recorded.
Similar Private Companies By Industry
|Calaire Chimie SAS||Europe|
|Merck Santé S.A.S.||Europe|
|Aptys Pharmaceuticals SAS||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Neuro3d S.A., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.